Examination of gene expression in single cancer cells not only provides a rationale for combinatorial anti‐VEGF and TKI therapies, particularly PD‐1‐directed therapies, but also paves the way for future investigations on the effects of ITH on primary or acquired resistance to targeted therapy. This evidence concerns the gene VEGFA and cancer.